TY - JOUR
T1 - An enteric pathogen Salmonella enterica serovar typhimurium suppresses tumor growth by downregulating CD44 high and CD4T regulatory (T reg) cell expression in mice
T2 - The critical role of lipopolysaccharide and Braun lipoprotein in modulating tumor growth
AU - Liu, T.
AU - Chopra, A. K.
N1 - Funding Information:
We thank Ms Mardelle Susman for assisting in paper preparation. This study was supported by NIH grant AI064389 to AK Chopra.
PY - 2010/2
Y1 - 2010/2
N2 - An antitumor activity associated with several bacterial pathogens, including Salmonella enterica serovar Typhimurium, has been reported; however, the underlying immunological mechanism(s) that lead to an antitumor effect are currently unclear. Furthermore, such pathogens cannot be used to suppress tumor growth because of their potential for causing sepsis. Recently, we reported the characterization of S. Typhimurium isogenic mutants from which Braun lipoprotein genes (lppA and B) and the multicopy repressor of high temperature requirement (msbB) gene were deleted. In a mouse infection model, two mutants, namely, lppB/msbB and lppAB/msbB, minimally induced proinflammatory cytokine production at high doses and were nonlethal to animals. We showed that immunization of mice with these mutants, followed by challenge with the wild-type S. Typhimurium, could significantly suppress tumor growth, as evidenced by an 88% regression in tumor size in lppB/msbB mutant-immunized animals over a 24-day period. However, the lppAB/msbB mutant alone was not effective in modulating tumor growth in mice, although the lppB/msbB mutant alone caused marginal regression in tumor size. Importantly, we showed that CD44 cells grew much faster than CD44 cells from human liver tumors in mice, leading us to examine the possibility that S. Typhimurium might downregulate CD44 in tumors and splenocytes of mice. Consequently, we found in S. Typhimurium-infected mice that tumor size regression could indeed be related to the downregulation of CD44 high and CD4 CD25 T reg cells. Importantly, the role of lipopolysaccharide and Braun lipoprotein was critical in S. Typhimurium-induced antitumor immune responses. Taken together, we have defined new immune mechanisms leading to tumor suppression in mice by S. Typhimurium.
AB - An antitumor activity associated with several bacterial pathogens, including Salmonella enterica serovar Typhimurium, has been reported; however, the underlying immunological mechanism(s) that lead to an antitumor effect are currently unclear. Furthermore, such pathogens cannot be used to suppress tumor growth because of their potential for causing sepsis. Recently, we reported the characterization of S. Typhimurium isogenic mutants from which Braun lipoprotein genes (lppA and B) and the multicopy repressor of high temperature requirement (msbB) gene were deleted. In a mouse infection model, two mutants, namely, lppB/msbB and lppAB/msbB, minimally induced proinflammatory cytokine production at high doses and were nonlethal to animals. We showed that immunization of mice with these mutants, followed by challenge with the wild-type S. Typhimurium, could significantly suppress tumor growth, as evidenced by an 88% regression in tumor size in lppB/msbB mutant-immunized animals over a 24-day period. However, the lppAB/msbB mutant alone was not effective in modulating tumor growth in mice, although the lppB/msbB mutant alone caused marginal regression in tumor size. Importantly, we showed that CD44 cells grew much faster than CD44 cells from human liver tumors in mice, leading us to examine the possibility that S. Typhimurium might downregulate CD44 in tumors and splenocytes of mice. Consequently, we found in S. Typhimurium-infected mice that tumor size regression could indeed be related to the downregulation of CD44 high and CD4 CD25 T reg cells. Importantly, the role of lipopolysaccharide and Braun lipoprotein was critical in S. Typhimurium-induced antitumor immune responses. Taken together, we have defined new immune mechanisms leading to tumor suppression in mice by S. Typhimurium.
KW - CD44
KW - Mouse model
KW - Salmonella Typhimurium and its mutants
KW - T regulatory (Treg) cells
KW - Tumor
UR - http://www.scopus.com/inward/record.url?scp=74649083142&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74649083142&partnerID=8YFLogxK
U2 - 10.1038/cgt.2009.58
DO - 10.1038/cgt.2009.58
M3 - Article
C2 - 19713997
AN - SCOPUS:74649083142
SN - 0929-1903
VL - 17
SP - 97
EP - 108
JO - Cancer gene therapy
JF - Cancer gene therapy
IS - 2
ER -